Home ProductsMedical Raw Materials

ISO9001 Proscar 98319-26-7 Medicine Raw Material Finasteride For Prostate Enlargement

Certification
Good quality Pharma Raw Material for sales
Good quality Pharma Raw Material for sales
I'm Online Chat Now

ISO9001 Proscar 98319-26-7 Medicine Raw Material Finasteride For Prostate Enlargement

China ISO9001 Proscar 98319-26-7 Medicine Raw Material Finasteride For Prostate Enlargement supplier
ISO9001 Proscar 98319-26-7 Medicine Raw Material Finasteride For Prostate Enlargement supplier ISO9001 Proscar 98319-26-7 Medicine Raw Material Finasteride For Prostate Enlargement supplier

Large Image :  ISO9001 Proscar 98319-26-7 Medicine Raw Material Finasteride For Prostate Enlargement

Product Details:

Place of Origin: China
Brand Name: PooChun
Certification: ISO9001 SGS HACCP
Model Number: 98319-26-7

Payment & Shipping Terms:

Minimum Order Quantity: Negotiable
Price: Negotiable
Packaging Details: 1~10 kg / Al-Pt bag,10kg / 25kg fiber drum
Delivery Time: 1-3days after payment
Payment Terms: T/T, L/C
Supply Ability: 100 ton per Month
Contact Now
Detailed Product Description
CAS: 98319-26-7 MF: C23H36N2O2
MW: 372.549 Shipping: DHL TNT FedEx HKEMS UPS
Payment Terms: T/T, Western Union, Paypal, Moneygram Use: Prostate Enlargement, Pattern Hair Loss
High Light:

steroid hormones

,

pharmaceutical intermediates

Proscar Medicine Raw Material Finasteride For Propecia Hair Regrowth Prostate enlargement

 


Description

 

Finasteride is a 5α - reductase inhibitor, specifically the type II and III isoenzymes. By inhibiting 5α - reductase, finasteride prevents conversion of testosterone to dihydrotestosterone ( DHT ) by the type II and III isoenzymes, resulting in a decrease in serum DHT levels by about 65–70% and in prostate DHT levels by up to 85–90%, where expression of the type II isoenzyme predominates. Unlike triple inhibitors of all three isoenzymes of 5α-reductase like dutasteride which can reduce DHT levels in the entire body by more than 99%, finasteride does not completely suppress DHT production because it lacks significant inhibitory effects on the 5α-reductase type I isoenzyme, with 100- fold less affinity for I as compared to II.

 

By blocking DHT production, finasteride reduces androgen activity in the scalp. In the prostate, inhibition of 5α - reductase reduces prostate volume, which improves BPH and reduces risk of prostate cancer. Inhibition of 5α - reductase also reduces epididymal weight, and decreases motility and normal morphology of spermatozoa in the epididymis. Neurosteroids like 3α - androstanediol and allopregnanolone activate the GABAA receptor; because finasteride prevents the formation of neurosteroids, it may contribute to a reduction of GABAA activity ( see also neurosteroidogenesis inhibitor ). Reduction of GABAA receptor activation by these neurosteroids has been implicated in depression, anxiety, and sexual dysfunction.

 

In addition to inhibiting 5α - reductase, finasteride has also been found to competitively inhibit 5β - reductase ( AKR1D1 ), although its affinity for the enzyme is substantially less than for 5α - reductase ( an order of magnitude less than 5α-reductase type I ) and hence is unlikely to be of clinical significance.

Finasteride reduces prostate volume by 20 to 30% in men with benign prostatic hyperplasia.

 

 

Usage

 

1. Prostate enlargement

 

Physicians sometimes use finasteride for the treatment of BPH, informally known as an enlarged prostate. Finasteride may improve the symptoms associated with BPH such as difficulty urinating, getting up during the night to urinate, hesitation at the start of urination, and decreased urinary flow. It provides less symptomatic relief than alpha -1 blockers such as tamsulosin and symptomatic relief is slower in onset ( six months or more of treatment with finasteride may be required to determine the therapeutic results of treatment ). Symptomatic benefits are mainly seen in those with prostate volume > 40 cm3. In long - term studies finasteride but not alpha-1 inhibitors reduce the risk of acute urinary retention ( −57% at 4 years ) and the need for surgery ( −54% at 4 years ). If the drug is discontinued, any therapeutic benefits reverse within about 6–8 months.

2. Pattern hair loss

 

Finasteride is sometimes used to treat pattern hair loss ( androgenetic alopecia ) in men only. Treatment slows further hair loss and provides about 30% improvement in hair loss after six months of treatment, with effectiveness usually only persisting as long as the drug is taken, although on occasion hair loss is slowed indefinitely following withdrawal. Finasteride has also been tested for pattern hair loss in women; the results were no better than placebo.

3. Excessive hair growth

 

Finasteride has been found to be effective in the treatment of hirsutism ( excessive facial and/or body hair growth ) in women. In a study of 89 women with hyperandrogenism due to persistent adrenarche syndrome, finasteride produced a 93% reduction in facial hirsutism and a 73% reduction bodily hirsutism after 2 years of treatment. Other studies using finasteride for hirsutism have also found it to be clearly effective.

4. Transgender women

 

Finasteride is sometimes used in hormone replacement therapy for transgender women due to its antiandrogen properties, in combination with a form of estrogen. However, little clinical research of finasteride use for this purpose has been conducted and evidence of efficacy is limited. Moreover, caution has been recommended when prescribing finasteride to transgender women, as finasteride may be associated with side effects such as depression, anxiety, and suicidal ideation, symptoms that are particularly prevalent in the transgender population and in others at high risk already.

 

 

 

Specification

 

Test Items Specification Test Results
Description White or off-white crystalline powder Off-white crystalline powder
Specific rotation -56°~-60° -58.2°
Identification IR Matches with working standard Complies
HPLC
Solubility Freely soluble in chloroform and in alcohol;
Very slightly soluble in water
Conform
Heavy metals ≤10ppm <10ppm
Water ≤0.3% 0.22%
Residue on ignition ≤0.1% 0.05%
Relative material Maximum impurities≤0.5% 0.36%
Total impurities≤1.0% 0.52%
Assay 98.5~101.0% 99.59%
Conclusion The specification conform with Enterprise standard

 

 

ISO9001 Proscar 98319-26-7 Medicine Raw Material Finasteride For Prostate Enlargement

Contact Details
Shanghai Poochun Industry Co.,Ltd

Send your inquiry directly to us (0 / 3000)